Arrowstreet Capital
CAPR icon

Arrowstreet Capital’s Capricor Therapeutics CAPR Stock Holding History

Arrowstreet Capital’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-101,542
Closed -$689K – 1542
2024
Q1 		$689K Buy
+101,542
New +$491K ﹤0.01% 1392

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Arrowstreet Capital's CAPR Position: Q2 2024 in Review

Arrowstreet Capital sold out of Capricor Therapeutics (CAPR) in Q2 2024, closing a stake of 101,542 shares — an estimated $689K sold.

Arrowstreet Capital first reported a position in CAPR in Q1 2024 and held it in 1 quarter. The position peaked at $689K in Q1 2024. 61 funds tracked by Wall St. Rank hold CAPR as of Q2 2024.

  • Arrowstreet Capital reported no remaining Capricor Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Arrowstreet Capital sold 101,542 Capricor Therapeutics shares in Q2 2024, an estimated $689K.
  • Arrowstreet Capital first reported a position in Capricor Therapeutics in Q1 2024 and held it in 1 quarter.
  • Arrowstreet Capital's Capricor Therapeutics position peaked at $689K in Q1 2024.
  • 61 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2024.

Based on Arrowstreet Capital's 13F filing for Q2 2024, filed 14 Aug 2024.